FOXP2 inhibits the aggressiveness of lung cancer cells by blocking TGFβ signaling

Wenya Su1, Song Hu1, Lin Zhou1

  • 1Department of Respiratory and Critical Care Medicine, Changzhou First People's Hospital, Changzhou, Jiangsu 213000, P.R. China.

Oncology Letters
|April 8, 2024
PubMed

Insights

Forkhead box P2 (FOXP2) acts as an antitumor gene in lung cancer, suppressing cell proliferation and migration. Inactivating TGF-beta signaling is key to FOXP2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer presents significant morbidity and mortality.
  • Forkhead box P2 (FOXP2) exhibits antitumor properties in several cancers.
  • The specific role of FOXP2 in lung cancer pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the function of FOXP2 in lung cancer.
  • To determine the impact of FOXP2 on lung cancer cell behavior.
  • To elucidate the molecular mechanisms underlying FOXP2's role in lung cancer.

Main Methods:

  • Quantitative reverse transcription PCR (RT-qPCR) for mRNA levels.
  • Western blotting for protein expression analysis.
  • Cell Counting Kit-8 (CCK-8), Transwell, and TUNEL assays for functional assessments.

Main Results:

  • FOXP2 expression was found to be downregulated in lung cancer tissues.
  • Overexpression of FOXP2 inhibited lung cancer cell proliferation, migration, and invasion.
  • FOXP2 promoted apoptosis in lung cancer cells and inactivated TGF-beta signaling.

Conclusions:

  • FOXP2 functions as a tumor suppressor gene in lung cancer.
  • FOXP2 mitigates malignant behaviors in lung cancer by inhibiting TGF-beta signaling.
  • Targeting FOXP2 or TGF-beta signaling may offer therapeutic strategies for lung cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K